INT113081

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2003
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 1.68
Pain Relevance 2.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Cyp1a2) endoplasmic reticulum (Cyp1a2) enzyme binding (Cyp1a2)
response to stress (Cyp1a2)
Anatomy Link Frequency
liver 2
Cyp1a2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Paracetamol 24 99.98 Very High Very High Very High
tolerance 11 98.44 Very High Very High Very High
antagonist 44 81.64 Quite High
headache 5 70.68 Quite High
Angina 1 64.40 Quite High
Serotonin 8 33.28 Quite Low
dexamethasone 10 5.00 Very Low Very Low Very Low
Opioid 7 5.00 Very Low Very Low Very Low
anesthesia 6 5.00 Very Low Very Low Very Low
Regional anesthesia 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Toxicity 7 99.92 Very High Very High Very High
Pressure Volume 2 Under Development 2 94.76 High High
Stress 2 75.00 Quite High
Hypersensitivity 1 72.16 Quite High
Headache 5 70.68 Quite High
Vomiting 111 67.84 Quite High
Cv General 3 Under Development 1 64.40 Quite High
Hepatotoxicity 2 63.40 Quite High
Dizziness 2 62.04 Quite High
Constipation 3 61.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Suppression of Cyp1A2 expression by pretreatment is assumed to be due to a growth-stimulating effect of low concentrations of acetaminophen.
Negative_regulation (Suppression) of Gene_expression (expression) of Cyp1A2 associated with paracetamol
1) Confidence 0.58 Published 2003 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12969438 Disease Relevance 0.30 Pain Relevance 0.59
Pretreatment and growth factors protect against acetaminophen toxicity by suppressing the expression of Cyp1A2, thereby reducing the production of the intermediate N-acetyl-p-benzoquinone imine (NAPQI).
Negative_regulation (suppressing) of Gene_expression (expression) of Cyp1A2 associated with toxicity and paracetamol
2) Confidence 0.58 Published 2003 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12969438 Disease Relevance 0.32 Pain Relevance 0.60
Two mechanisms, as follows in order of importance, are responsible for the effect of liver dysfunction: (1) decreased sensitivity to fluvoxamine of CYP1A2-mediated biotransformations in the cirrhotic liver, probably resulting from reduced uptake of the inhibitory drug, and (2) reduced hepatic expression of CYP1A2, which makes its contribution to overall drug elimination less important.


Negative_regulation (reduced) of Gene_expression (expression) of CYP1A2 in liver
3) Confidence 0.54 Published 2006 Journal Clin. Pharmacol. Ther. Section Body Doc Link 16678550 Disease Relevance 0 Pain Relevance 0
The administration of ACET down-regulated CYP1A2 and CYP2B1 expression in CD rats, while up-regulating them in NF rats.
Negative_regulation (down-regulated) of Gene_expression (expression) of CYP1A2 associated with paracetamol
4) Confidence 0.41 Published 2009 Journal J Appl Toxicol Section Abstract Doc Link 18798224 Disease Relevance 0 Pain Relevance 0.59
Cardiac P450 expression (CYP1A2) assessed by immunoblotting, markedly decreased 48 h after NTG administration in control rats.
Negative_regulation (decreased) of Gene_expression (expression) of CYP1A2
5) Confidence 0.37 Published 2006 Journal Free Radic. Biol. Med. Section Abstract Doc Link 16520233 Disease Relevance 0.23 Pain Relevance 0.41
Palonosetron does not cause inhibition or induction of the main hepatic enzyme systems including CYP2D6, CYP1A2 and CYP3A4/5, so the risk of significant drug interactions is low.119 However an adverse reaction with apomorphine that presented as profound hypotension and altered consciousness has been reported, so concomitant use is contraindicated.128


Negative_regulation (inhibition) of Gene_expression (/) of CYP1A2 associated with pressure volume 2 under development
6) Confidence 0.05 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697527 Disease Relevance 0.83 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox